Exploring Analyst Estimates for AtriCure (ATRC) Q4 Earnings, Beyond Revenue and EPS

Core Insights - Analysts project AtriCure (ATRC) will report a quarterly loss of $0.15 per share, reflecting a 28.6% increase year over year, with revenues expected to reach $124.3 million, a 16.7% increase from the same quarter last year [1] Revenue Estimates - The consensus estimate for 'United States Revenue- Pain management' is $16.48 million, indicating a year-over-year change of +27.2% [4] - Analysts estimate 'United States Revenue- Total ablation' at $60.11 million, suggesting a +13.6% change from the prior-year quarter [4] - 'International Revenue- Total ablation' is projected to reach $13.30 million, reflecting a +19.6% year-over-year change [4] - The average prediction for 'United States Revenue- Total' stands at $99.69 million, indicating a +12.3% change year over year [5] - 'International Revenue- Appendage management' is expected to be $8.45 million, showing a +26.7% increase from the year-ago quarter [5] - 'United States Revenue- Open ablation' is forecasted to reach $31.84 million, indicating a +16.7% year-over-year change [5] - 'International Revenue- Open ablation' is estimated at $9.53 million, reflecting a +12.6% change from the year-ago quarter [6] - 'United States Revenue- Minimally invasive ablation' is projected to be $11.79 million, indicating a -7% change year over year [6] - 'United States Revenue- Appendage management' is expected to be $39.55 million, suggesting a +10.4% year-over-year change [7] - 'International Revenue- Total' is forecasted to reach $21.74 million, indicating a +22.2% change year over year [7] Stock Performance - AtriCure shares have increased by +22.2% over the past month, outperforming the +4.2% move of the Zacks S&P 500 composite [8] - AtriCure holds a Zacks Rank 3 (Hold), indicating expectations to mirror overall market performance in the near future [8]